Oculogica
Oculogica develops FDA-cleared, eye-tracking-based concussion diagnostic devices (EyeBOX and SNAP) that detect cranial-nerve-mediated eye movement disruption to deliver objective, baseline-free concussion assessment in under four minutes or 90 seconds for sports medicine, pediatric, military, urgent care, and personal injury/IME clinical settings.
- Company typePrivate
- Founded2013
- HeadquartersNew York, United States
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What Oculogica does
Oculogica is a privately-held neuro-diagnostics company founded in 2013 that develops and commercializes FDA-cleared, eye-tracking-based concussion assessment devices. The company sells two products: EyeBOX, an in-clinic device that captures and analyzes 100,000 data points of cranial-nerve-mediated eye movements via infrared tracking to produce a BOX Score and 14 additional metrics in under four minutes without requiring a pre-injury baseline; and SNAP, a portable, battery-powered 90-second multimodal assessment that combines eye-tracking metrics with patient-reported symptom severity to produce a SNAP Score with 90% sensitivity and 94% specificity. Both products target clinical decision-making for concussion and mild traumatic brain injury in settings ranging from sports medicine clinics and pediatric urgent care to military/veteran facilities and personal injury/IME workflows.
Oculogica generates revenue primarily through capital equipment sales of EyeBOX and SNAP to hospitals, sports medicine clinics, urgent care facilities, VA/military medical centers, and research institutions, supplemented by training and support services. Pricing is not publicly disclosed; the company uses a consultative, quote-based sales motion initiated through a "Request a Demo" web form. Distribution combines direct enterprise field sales (e.g., Mayo Clinic, Rush University), an inside sales motion for mid-market clinics, and channel partners — notably XcelABLE, which embeds EyeBOX into Functional Capacity Evaluations and Independent Medical Examinations across all 50 U.S. states and globally, and the TRANSCENDENT Concussion Research Program in Ontario, Canada, which serves as the company's first (and currently only) Canadian site. The company holds six FDA clearances for concussion diagnostics — the most of any company in the industry — including the first FDA De Novo authorization for a baseline-free concussion test (December 2018) and the broadest label expansion in the industry (April 2025, ages 5-67, any time since injury, any injury type).
Operationally, Oculogica is a lean organization (1-10 employees) led by CEO Dr. Rosina Samadani, with founder Dr. Uzma Samadani serving as Scientific Advisor. The company is incorporated in Delaware with principal operations in New Richmond, Wisconsin. It has raised approximately $11M+ in disclosed funding from accredited investors, angel groups (Golden Seeds, Nebraska Angel Network, Southeast Minnesota Capital Fund, Sofia Fund), venture capital (TitletownTech, Colle Capital Partners), and U.S. government sources (Department of Defense, U.S. Army Medical Research & Development Command), with a $17.95M SEC exempt securities offering filed in May 2024. Technology credibility is supported by 16 peer-reviewed publications spanning 2014-2025 across journals including Military Medicine, Neurology, Journal of Neurotrauma, and Journal of Neurosurgery.
Oculogica firmographics
Firmographics- Name
- Oculogica
- Legal name
- Oculogica, Inc.
- Website
- https://oculogica.com
- Company type
- Private
- Founded year
- 2013
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Oculogica develops FDA-cleared, eye-tracking-based concussion diagnostic devices (EyeBOX and SNAP) that detect cranial-nerve-mediated eye movement disruption to deliver objective, baseline-free concussion assessment in under four minutes or 90 seconds for sports medicine, pediatric, military, urgent care, and personal injury/IME clinical settings.
- Ownership category
- akta.pro rank
Oculogica industry classification
Industry- Product category
- Concussion Diagnostic Devices
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (33451)
- SIC
- Surgical & Medical Instruments & Apparatus (3841), Electromedical & Electrotherapeutic Apparatus (3845)
- akta.pro primary industry
- Visual Field & Functional Vision Testing (Perimetry, ERG/VEP, Contrast Sensitivity) (HLAHAJAC)
- akta.pro secondary industry
- Pediatric Ophthalmology & Orthoptics Devices (Amblyopia Therapy, Strabismus Measurement & Treatment) (HLAHAJAM)
Keywords
Where Oculogica is headquartered
LocationHeadquarters
- HQ city
- New York
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
Oculogica business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Marketing or Sales, Supply Chain, Operations
Revenue model
- Medical Device Sales (EyeBOX and SNAP): Oculogica sells its FDA-cleared concussion diagnostic devices — EyeBOX (in-clinic, 4-minute assessment) and SNAP (portable sideline assessment) — to healthcare providers. Device sales to hospitals, sports medicine clinics, urgent care facilities, VA/military medical centers, and research institutions represent the primary revenue stream. Pricing is quote-based; no public pricing is listed.
- Training and Support Services: Oculogica provides device training and support to EyeBOX customers, including live training scheduling, training video libraries, and report interpretation guidance. Training videos are accessible to EyeBOX customers only, suggesting training/support may be bundled or offered as an ancillary service tied to device adoption.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Quote-based device pricing for EyeBOX and SNAP |
Go-to-market motion3 records
Distribution channels4 records
Marketing channels8 records
Oculogica product offering
Product offeringCore offering
Oculogica develops and sells FDA-cleared concussion diagnostic medical devices built on proprietary eye-tracking technology. Its two commercial products are EyeBOX®, an in-clinic device that delivers an objective concussion assessment in under 4 minutes by analyzing 100,000 data points of cranial nerve-mediated eye movements, and SNAP™, a portable 90-second multimodal test combining eye-tracking with symptom severity for sideline and clinic use. Both products generate objective concussion scores without requiring pre-injury baselines and are cleared for ages 5-67 across any injury type and any time since injury.
Product overview
Oculogica offers two FDA-cleared concussion diagnostic products built on proprietary eye-tracking technology: EyeBOX and SNAP. EyeBOX is an in-clinic device providing objective concussion assessment in under 4 minutes without requiring a pre-injury baseline, cleared for ages 5-67. SNAP is a portable, 90-second concussion screening tool designed for sideline and clinical use, combining eye-tracking metrics with symptom input for rapid multimodal assessment. Both products use the same underlying eye-tracking science to detect concussion-related disruptions in cranial nerve function. The company has received six total FDA clearances for concussion diagnostics, the most of any company in the industry.
Differentiator
Problem solved
Functional benefit
Brands
- EyeBOX: FDA-cleared concussion diagnostic device that uses proprietary eye-tracking technology to measure abnormal eye movements caused by concussion. Provides objective data independent of patient-reported symptoms. Delivers results in under 4 minutes without requiring a pre-injury baseline. Cleared for ages 5 to 67.
- SNAP
Products and services
- EyeBOX® Concussion Diagnostic FDA-cleared in-clinic concussion diagnostic device using proprietary eye-tracking technology. Captures and analyzes 100,000 data points of cranial-nerve-mediated eye movements during a non-invasive 4-minute assessment while the patient watches a video stimulus. Generates an objective BOX Score and 14 additional metrics compared against an age- and gender-normalized population. No pre-injury baseline, symptom input, language, or literacy required. Cleared for ages 5 to 67, any time since injury, any injury type. Targets hospitals, sports medicine clinics, urgent care, VA/military, personal injury clinics, and concussion research institutions.
- SNAP™ Concussion Test® FDA-cleared 90-second multimodal concussion test combining infrared eye tracking with patient-reported symptom severity to produce a composite SNAP Score. Portable, battery-powered, rugged form factor that works indoors and outdoors without requiring a pre-injury baseline. Achieves 90% sensitivity and 94% specificity. Designed for athletic trainers and urgent care clinicians for sideline screening and clinic use with adolescents and young adults.
Quantifiable outcome
- SNAP achieved 90% sensitivity and 94% specificity in FDA 510(k) validation studies — the highest accuracy of any concussion test cleared by the FDA
- +4 more outcomes
Companies that use Oculogica
Customer profileNamed customers8 records
Segments7 records
Ideal customer profiles5 records
Oculogica technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability4 records
Feature4 records
Oculogica partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered core.
- XcelABLEcoreXcelABLE, a global provider of Functional Capacity Evaluations (FCEs) and Independent Medical Examinations (IMEs), has partnered with Oculogica to include EyeBOX concussion diagnostics in all XcelABLE evaluations across all 50 U.S. states and globally. The partnership covers XcelABLE's credentialed clinician network and supports ongoing multi-university studies on biopsychosocial factors influencing concussion recovery. EyeBOX is integrated as an integral component of XcelABLE's FCE and IME offerings, providing objective data on concussion and TBI status to employers, insurers, and attorneys.
- Ontario Brain Institute (OBI)coreThe Ontario Brain Institute funds and supports the TRANSCENDENT Concussion Research Program, a research collaboration that is the first and only site in Canada to offer EyeBOX. OBI's provincial funding enables research-to-clinical deployment of Oculogica's technology, establishing EyeBOX as Health Canada registered diagnostic equipment in Canadian concussion care pathways.
- CHEO (Children's Hospital of Eastern Ontario) Research InstitutecoreCHEO Research Institute leads the TRANSCENDENT Concussion Research Program in Canada. Dr. Roger Zemek serves as Senior Scientist at CHEO Research Institute and leads research teams in Ottawa and Toronto. CHEO's research endorsement and clinical infrastructure enable EyeBOX's Canadian adoption and clinical validation. CHEO is affiliated with the University of Ottawa.
- 360 Concussion Carecore360 Concussion Care is a multi-specialty concussion clinic (Ottawa, Toronto, Mississauga) that is part of the TRANSCENDENT Concussion Research Program. As a clinic network, it offers EyeBOX as part of its concussion care services and ongoing research, serving as a clinical distribution channel for Oculogica's technology in Canada.
Scale indicators5 records
Oculogica competitors and assessment
Company assessmentDirect peers
- SyncThink: SyncThink develops eye-tracking-based concussion diagnostic technology (Eyesync) used in clinical and sports settings. It is the most direct head-to-head competitor to Oculogica's EyeBOX in the eye-tracking concussion diagnostic category, with comparable clinical positioning and FDA-cleared products.
- BrainScope: BrainScope manufactures FDA-cleared EEG-based devices (BrainScope Ahead) for objective concussion and mild TBI assessment. It is a direct peer to Oculogica as an objective, FDA-cleared concussion diagnostic serving emergency departments, urgent care, and military customers.
- RightEye: RightEye builds FDA-cleared eye-tracking diagnostic systems used to assess brain and vision health, including concussion and TBI applications. It overlaps directly with Oculogica's eye-tracking approach to concussion assessment while also addressing broader functional vision and neurological screening.
Broad incumbents
- ImPACT Applications: ImPACT Applications is the established leader in computer-based neurocognitive concussion testing (ImPACT, ImPACT Pediatric), with broad adoption across sports leagues and clinical practices. It is a broad incumbent competing for the same clinical decision points that Oculogica targets, but with a fundamentally different (subjective) testing modality.
Emerging players
- Quadrant Biosciences: Quadrant Biosciences develops saliva-based biomarker concussion diagnostics (e.g., the Clarifi MDx test). It is an emerging player addressing the same concussion diagnostic use case as Oculogica but with a fundamentally different biological sample modality.
- Sway Medical: Sway Medical provides FDA-cleared balance and motion-based concussion assessment tools used by athletic trainers and clinicians. It addresses the same sideline and clinical concussion triage workflows that Oculogica's SNAP targets, using a complementary biomechanical modality.
- HeadCheck Health: HeadCheck Health offers a concussion assessment and management platform combining symptom evaluation with clinical decision support for sports medicine. It overlaps with Oculogica in the sideline concussion assessment workflow but is software-led rather than hardware-device-led.
- C3 Logix: C3 Logix develops multimodal concussion assessment tools incorporating neurocognitive, balance, and eye-tracking components. It overlaps with Oculogica in the clinical and sports medicine concussion assessment market, particularly with eye-tracking feature overlap.
- X2 Biosystems: X2 Biosystems produces wearable sensor-based concussion assessment tools (X-Patch) used in contact sports. It is an emerging player competing in the same sideline and clinical concussion evaluation workflows as Oculogica's SNAP.
- NeuroSync: NeuroSync (acquired by SyncThink) develops VR-based eye-tracking assessment technology for concussion. It represents an emerging modality competing in the same objective concussion diagnostic space that Oculogica's eye-tracking products serve.
Market position
Strengths5 records
Weaknesses5 records
Key risks6 records
Key highlights7 records
Customer concentration
Oculogica social profiles
Digital presenceOculogica financial estimates
Financial estimateRevenue estimate
Valuation estimate
Oculogica leadership team
Management profileNumber of profiles
Profiles6 records
Oculogica funding detail
Funding detailFunding overview
Funding rounds9 records
Investors7 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Oculogica M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Oculogica
What does Oculogica do?
Oculogica develops and sells FDA-cleared concussion diagnostic medical devices built on proprietary eye-tracking technology. Its two commercial products are EyeBOX®, an in-clinic device that delivers an objective concussion assessment in under 4 minutes by analyzing 100,000 data points of cranial nerve-mediated eye movements, and SNAP™, a portable 90-second multimodal test combining eye-tracking with symptom severity for sideline and clinic use. Both products generate objective concussion scores without requiring pre-injury baselines and are cleared for ages 5-67 across any injury type and any time since injury.
Is Oculogica a public or private company?
Oculogica is a private company. It is classified as venture growth investor backed and is currently operating.
When was Oculogica founded?
Oculogica was founded in 2013. It employs 1 to 10 people.
Where is Oculogica based?
Oculogica is headquartered in New York, United States, in the North America region.
How does Oculogica make money?
Two revenue lines are on record. Medical Device Sales (EyeBOX and SNAP) is the primary driver. The others are training and Support Services.
Who are Oculogica's main competitors?
Direct peers on record are SyncThink, BrainScope and RightEye. ImPACT Applications is listed as a broad incumbent. Emerging players are Quadrant Biosciences, Sway Medical, HeadCheck Health, C3 Logix, X2 Biosystems and NeuroSync.
Does Oculogica have an API?
No public API is recorded for Oculogica.
What industry is Oculogica in?
Oculogica's product category is Concussion Diagnostic Devices. Its primary akta.pro industry code is HLAHAJAC, Visual Field & Functional Vision Testing (Perimetry, ERG/VEP, Contrast Sensitivity), with a secondary code of HLAHAJAM, Pediatric Ophthalmology & Orthoptics Devices (Amblyopia Therapy, Strabismus Measurement & Treatment). Its NAICS code is 334510 and its SIC code is 3841.